

**Patient Information:**

- **Name:** Isabel Janelle Crane (ID SYN064)
- **born:** 28/01/1975

**Primary Diagnosis (24/05/2023):** ROS1-positive NSCLC with isolated brain metastasis

- **Molecular Profile:** ROS1 fusion (confirmed via Archer FusionPlex, partner gene CD74)  
PD-L1 Status: TPS 28%, CPS 30, IC 2+ (SP263)

**Treatment Course:**

- **Start Date:** 15/06/2023 - Entrectinib 600 mg PO daily

**Clinical Course:** Ms. Crane presented with acute-onset aphasia and confusion. Brain MRI showed a solitary 1.6 cm left temporal lobe lesion with surrounding edema. Craniotomy was performed with complete resection and histology confirmed metastatic adenocarcinoma.

Molecular testing from tumor revealed ROS1-CD74 fusion. Entrectinib was initiated with good tolerability. At 6 weeks, restaging brain MRI showed no new lesions. Whole-body PET-CT showed sub-centimeter mediastinal nodes and no extracranial disease.

Follow-up at 9 months: remains asymptomatic, ECOG 0. MRI brain (March 2024) remains clear. Serial plasma ctDNA ROS1-fusion levels undetectable.

**Comorbidities:**

- Anxiety disorder (managed with sertraline)
- History of concussion (2019)

**Plan:**

- Continue entrectinib
- MRI brain every 8–12 weeks
- Consider lorlatinib upon CNS progression
- Monitor neurocognitive status

---

Signed by Dr. Gatsby, 24th March 2024